TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid tablets
Description: 1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid tablets
Description: 1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
Study: NCT03140722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: epoetin alfa
Study: NCT02514213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2mg INO-5150 and electroporation device CELLECTRA®-5P
Description: 2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
Description: 8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
Description: 2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
Study: NCT01574131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: pill every day for 6 months
Study: NCT02033616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVOVA-1
Description: Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MC
Description: Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
Study: NCT02381470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: Cefadroxil 1g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10mg/kg
Study: NCT03239301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic REhabilitation
Description: The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
Study: NCT00808405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 400mg taken orally three times daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo taken orally three times daily for 5 days.
Study: NCT02731846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
Study: NCT02514213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
Description: 8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation using CELLECTRA®-5P
Description: Electroporation device CELLECTRA®-5P

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation using CELLECTRA®-5P
Description: Electroporation device CELLECTRA®-5P

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation using CELLECTRA®-5P
Description: Electroporation device CELLECTRA®-5P

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation using CELLECTRA®-5P
Description: Electroporation device CELLECTRA®-5P
Study: NCT05516615

Intervention type: OTHER
Intervention: 4 minute breathing maneuver
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.

Intervention type: OTHER
Intervention: 4 minute breathing maneuver
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
Study: NCT00740194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibition
Description: Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Dermestril
Study: NCT00854867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radio Therapy (WBRT) with sequential Depocyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) with concomitant Depocyte
Study: NCT00914719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual risk reduction intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual risk reduction + alcohol risk reduction component
Study: NCT00935961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + docetaxel + cisplatin
Description: Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
Study: NCT01088204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy assisted distal gastrectomy
Description: laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal gastrectomy
Description: open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
Study: NCT06351163

Intervention type: PROCEDURE
Intervention: Laparoscopic reduction
Description: A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.

Intervention type: PROCEDURE
Intervention: Transumbilical mini-open reduction
Description: If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
Study: NCT03248167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 600 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
Study: NCT06238336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy
Description: The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
Study: NCT02284815

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutenfree diet
Description: Newly diagnosed children could choose glutenfree diet
Study: NCT01786382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Study: NCT04186533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
Study: NCT01930422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS procedure
Description: The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
Study: NCT00149799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
Study: NCT03747796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: The children will be placed in the supine position after ingestion of a standard volume of clear fluid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-sitting position
Description: The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
Study: NCT01483235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced cardiac rehabilitation group intervention (rCRP).
Description: The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiac rehabilitation intervention
Description: The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
Study: NCT02584452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: 20cc of 2% mepivacaine \<20 minutes prior to in room time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: 20cc of 2% mepivacaine \<20 minutes prior to in room time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal continuous nerve catheter
Description: Placement of ultrasound guided adductor canal continuous nerve catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline as bolus followed by bupivacaine
Description: normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal nerve block
Description: ultrasound guided adductor canal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine and dexamethasone
Description: 10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia induction will include a propofol bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia induction will include a propofol bolus.
Study: NCT01451957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - caloric balance
Description: 90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Exercise - hyper-caloric diet
Description: Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise - caloric balance
Description: Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
Study: NCT00564265

Intervention type: OTHER
Intervention: Observation
Description: Not applied
Study: NCT03116841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20 mg
Study: NCT00122317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Study: NCT02252068

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I-CBT
Description: New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CBT
Description: New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IDC
Description: Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
Study: NCT02778425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE+beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.